HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues

肝细胞癌 乙型肝炎表面抗原 医学 内科学 乙型肝炎病毒 胃肠病学 肿瘤科 病毒学 癌症研究 病毒
作者
Terry Cheuk‐Fung Yip,Grace Lai‐Hung Wong,Henry Lik‐Yuen Chan,Yee‐Kit Tse,Kelvin Long‐Yan Lam,Grace Lui,Vincent Wai‐Sun Wong
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:70 (3): 361-370 被引量:242
标识
DOI:10.1016/j.jhep.2018.10.014
摘要

•Patients without complete viral suppression have the highest risk of HCC.•NA-induced HBsAg seroclearance leads to lower HCC risk than complete viral suppression alone.•Patients with HBsAg seroclearance and complete viral suppression have a similar risk of hepatic events. Background & AimsIn treated patients with chronic hepatitis B (CHB) who have achieved complete viral suppression, it is unclear if functional cure as indicated by hepatitis B surface antigen (HBsAg) seroclearance confers additional clinical benefit. We compared the risk of hepatocellular carcinoma (HCC) and hepatic events in nucleos(t)ide analogue (NA)-treated patients with and without HBsAg seroclearance.MethodsWe performed a territory-wide retrospective cohort study on all patients with CHB who had received entecavir and/or tenofovir disoproxil fumarate (TDF) for at least 6 months between 2005 and 2016 from Hospital Authority, Hong Kong. Patients’ demographics, comorbidities, and laboratory parameters were analyzed. The primary outcome was HCC. The secondary outcomes were hepatic events including cirrhotic complications, liver transplantation, and liver-related mortality.ResultsA total of 20,263 entecavir/TDF-treated patients with CHB were identified; 17,499 (86.4%) patients had complete viral suppression; 376 (2.1%) achieved HBsAg seroclearance. At a median (interquartile range) follow-up of 4.8 (2.8–7.0) years, 603 (3.5%) and 121 (4.4%) patients with and without complete viral suppression developed HCC; 2 (0.5%) patients with HBsAg seroclearance developed HCC. Compared to complete viral suppression, lack of complete viral suppression was associated with a higher risk of HCC (7.8% vs. 5.6% at 8 years, Gray’s test, p <0.001) (adjusted hazard ratio [aHR] 1.69; 95% CI 1.36–2.09; p <0.001); patients who achieved functional cure had a lower risk of HCC (0.6% vs. 5.6% at 8 years, Gray’s test, p <0.001) (aHR 0.24; 95% CI 0.06–0.97; p = 0.045) but not hepatic events (aHR 0.99; 95% CI 0.30–3.26; p = 0.991).ConclusionsPatients who achieved HBsAg seroclearance on top of complete viral suppression with entecavir/TDF treatment may have a lower risk of HCC but not hepatic events.Lay summaryWe investigated 20,263 nucleos(t)ide analogue (NA)-treated patients with chronic hepatitis B. Patients with NA-induced hepatitis B surface antigen seroclearance on top of complete viral suppression have a lower risk of hepatocellular carcinoma but not hepatic events than those only achieving complete viral suppression under prolonged NA treatment. In treated patients with chronic hepatitis B (CHB) who have achieved complete viral suppression, it is unclear if functional cure as indicated by hepatitis B surface antigen (HBsAg) seroclearance confers additional clinical benefit. We compared the risk of hepatocellular carcinoma (HCC) and hepatic events in nucleos(t)ide analogue (NA)-treated patients with and without HBsAg seroclearance. We performed a territory-wide retrospective cohort study on all patients with CHB who had received entecavir and/or tenofovir disoproxil fumarate (TDF) for at least 6 months between 2005 and 2016 from Hospital Authority, Hong Kong. Patients’ demographics, comorbidities, and laboratory parameters were analyzed. The primary outcome was HCC. The secondary outcomes were hepatic events including cirrhotic complications, liver transplantation, and liver-related mortality. A total of 20,263 entecavir/TDF-treated patients with CHB were identified; 17,499 (86.4%) patients had complete viral suppression; 376 (2.1%) achieved HBsAg seroclearance. At a median (interquartile range) follow-up of 4.8 (2.8–7.0) years, 603 (3.5%) and 121 (4.4%) patients with and without complete viral suppression developed HCC; 2 (0.5%) patients with HBsAg seroclearance developed HCC. Compared to complete viral suppression, lack of complete viral suppression was associated with a higher risk of HCC (7.8% vs. 5.6% at 8 years, Gray’s test, p <0.001) (adjusted hazard ratio [aHR] 1.69; 95% CI 1.36–2.09; p <0.001); patients who achieved functional cure had a lower risk of HCC (0.6% vs. 5.6% at 8 years, Gray’s test, p <0.001) (aHR 0.24; 95% CI 0.06–0.97; p = 0.045) but not hepatic events (aHR 0.99; 95% CI 0.30–3.26; p = 0.991). Patients who achieved HBsAg seroclearance on top of complete viral suppression with entecavir/TDF treatment may have a lower risk of HCC but not hepatic events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
丽丽发布了新的文献求助10
2秒前
3秒前
帅玉玉完成签到,获得积分10
4秒前
Remote完成签到,获得积分10
5秒前
w婷完成签到 ,获得积分10
5秒前
ruochenzu发布了新的文献求助10
5秒前
取法乎上完成签到 ,获得积分10
5秒前
淡定自中完成签到 ,获得积分10
5秒前
大橙子发布了新的文献求助10
7秒前
alanbike完成签到,获得积分10
8秒前
哈基米德应助丽丽采纳,获得20
9秒前
隐形曼青应助able采纳,获得10
14秒前
咸鱼已躺平完成签到,获得积分10
16秒前
诡异的饭团完成签到,获得积分10
17秒前
anan完成签到 ,获得积分10
18秒前
常绝山完成签到 ,获得积分10
18秒前
幽默皮皮虾完成签到,获得积分10
18秒前
易止完成签到 ,获得积分10
18秒前
just完成签到,获得积分10
19秒前
21秒前
Disguise完成签到,获得积分10
21秒前
Young4399完成签到 ,获得积分10
21秒前
火星上宛秋完成签到 ,获得积分10
22秒前
22秒前
22秒前
量子星尘发布了新的文献求助10
22秒前
szh123完成签到 ,获得积分10
23秒前
Luke发布了新的文献求助10
25秒前
mauve完成签到 ,获得积分10
25秒前
丽丽完成签到,获得积分10
29秒前
敏感笑槐完成签到 ,获得积分10
30秒前
Luke完成签到,获得积分10
30秒前
得鹿梦鱼完成签到,获得积分10
31秒前
嗝嗝完成签到,获得积分10
33秒前
Perry应助科研通管家采纳,获得30
33秒前
33秒前
今后应助水晶茶杯采纳,获得10
33秒前
peterlzb1234567完成签到,获得积分10
35秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022